Pharmacoeconomics: Open Access

Foula Televantou

Publications

• Research Article
  Atomoxetine for the Treatment of Adults with Attention Deficit Hyperactivity Disorder: A Cost-Utility Analysis in Spain
  Author(s): Antje Tockhorn, Foula Televantou, Kristina Karlsdotter and Tatiana DillaAntje Tockhorn, Foula Televantou, Kristina Karlsdotter and Tatiana Dilla
  
  Background: Attention-deficit hyperactivity disorder (ADHD) frequently persists into adulthood and leads to a significant burden of illness. Many adults with ADHD suffer from comorbid conditions such as substance and alcohol use disorders and anxiety. Atomoxetine is the only drug therapy approved in Spain for the treatment of adult ADHD. This study estimates the cost-utility of atomoxetine compared with no treatment in adults with ADHD in Spain and in two specific subgroups: patients with comorbid anxiety or comorbid alcohol abuse. Method: A simple, state-transition Markov model with three health-states (treatment initiation, response and no-response) was developed. The model estimated the incremental cost per quality-adjusted life year (QALY). Treatment effectiveness and discontinuation rates were estimated from nine atomoxetine clinical trial.. Read More»
  DOI: 10.4172/2472-1042.1000104

  Abstract PDF